Log in

CNSX:IMEImagin Medical Stock Price, Forecast & News

-0.01 (-25.00 %)
(As of 07/10/2020 04:00 PM ET)
Today's Range
Now: C$0.03
50-Day Range
MA: C$0.04
52-Week Range
Now: C$0.03
Volume145,000 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Imagin Medical Inc. engages in developing imaging solutions for the early detection of cancer through the use of endoscopes. Its ultrasensitive imaging technology is based on improved optical designs and advanced light sensors for detecting cancer, as well as visualize, identify, and remove cancerous cells. The company's target market is bladder cancer. Imagin Medical Inc. is headquartered in Vancouver, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.12 out of 5 stars

Industry, Sector and Symbol

Industry Diagnostics & Research



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive IME News and Ratings via Email

Sign-up to receive the latest news and ratings for IME and its competitors with MarketBeat's FREE daily newsletter.

Imagin Medical (CNSX:IME) Frequently Asked Questions

Has Imagin Medical been receiving favorable news coverage?

Press coverage about IME stock has trended neutral recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Imagin Medical earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Imagin Medical.

Who are some of Imagin Medical's key competitors?

What other stocks do shareholders of Imagin Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Imagin Medical investors own include Nemaska Lithium (NMX), Aurora Cannabis (ACB), Aphria (APHA), Heat Biologics (HTBX), Sesen Bio (SESN), VersaBank (VB), Abcourt Mines (ABI), Cordoba Minerals (CDB), Chemesis International (CADMF) and Aequus Pharmaceuticals (AQS).

Who are Imagin Medical's key executives?

Imagin Medical's management team includes the following people:
  • Mr. Edward James Hutchens, CEO, Pres & Director
  • Mr. John F. Vacha, CFO, Corp. Sec. & Director
  • Mr. Thom McMahon, Director of Sales

What is Imagin Medical's stock symbol?

Imagin Medical trades on the CNSX under the ticker symbol "IME."

What is Imagin Medical's stock price today?

One share of IME stock can currently be purchased for approximately C$0.03.

What is Imagin Medical's official website?

The official website for Imagin Medical is imaginmedical.com.

How can I contact Imagin Medical?

Imagin Medical's mailing address is 890 Pender St W Suite 600, VANCOUVER, BC V6C 1J9, Canada. The company can be reached via phone at +1-604-6623903.

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.